Stockwatch: Game, Pharmasset, and Match?
This article was originally published in Scrip
Just at the moment when markets are more focused on sovereign debt crises and Wall Street is thinking about squatters on its doorstep and looking forward to Thanksgiving, Gilead Sciences steps up and makes an audacious all cash $11 billion bid for Pharmasset. The planned acquisition, which has the full backing of the Pharmasset board, raises more questions than it answers.
Register for our free email digests: